In the latest market close, Eli Lilly (LLY) reached $932.50, with a +1.58% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.07%. Meanwhile, the Dow experienced a drop of 0.13%, and the technology-dominated Nasdaq saw an increase of 0.14%. The drugmaker's shares have seen an increase of 6.13% over the last month, surpassing the Medical sector's loss of 1.99% and the S&P 500's gain of 4.34%. The investment community will be paying close attention to the earnings performance of Eli Lilly in its upcoming release. The company is slated to reveal its earnings on August 8, 2024. The company's upcoming EPS is projected at $2.65, signifying a 25.59% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $9.8 billion, indicating a 17.96% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates project earnings of $13.61 per share and a revenue of $42.87 billion, demonstrating changes of +115.35% and +25.62%, respectively, from the preceding year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.04% upward. Currently, Eli Lilly is carrying a Zacks Rank of #3 (Hold). Looking at valuation, Eli Lilly is presently trading at a Forward P/E ratio of 67.45. For comparison, its industry has an average Forward P/E of 14.72, which means Eli Lilly is trading at a premium to the group. Also, we should mention that LLY has a PEG ratio of 2.02. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.84. The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 99, this industry ranks in the top 40% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eli Lilly and Company (LLY):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...